Cells and mice
In Lee and colleagues’ mouse study, MOTS-c was linked with reduced weight gain and better control of blood sugar.
- This is animal evidence, so it does not show the result of treatment in people.
MOTS-c guidebook
Read the claim. Then read the study.
Read what a study actually did before carrying its result into a care decision.
Compare the evidence by what was tested
Similar-sounding studies can answer very different questions. Check what was tested and who took part.
ClinicalTrials.gov is a public website that lists study plans and any results posted there.
The body’s own MOTS-c
Human studies have measured MOTS-c levels in blood or muscle, including around exercise.
- These studies reported links between the body’s MOTS-c levels and things such as exercise. Those links do not prove that giving people MOTS-c helps.
A different substance
CB4211 is a company-made substance based on MOTS-c, but it is different from MOTS-c itself.
- As of September 30, 2026, the CB4211 study was finished, but its results were not public on ClinicalTrials.gov or in a medical journal.
- The company’s own report of its findings cannot show what MOTS-c itself does.
MOTS-c itself
At the September 30, 2026 check, ClinicalTrials.gov described study NCT07505745 in China as looking for people to take part, with no results posted.
- A study plan does not tell us whether the treatment helped.
What the pharmacy rules and FDA review mean
FDA means Food and Drug Administration. Its MOTS-c review looked at whether pharmacies could use the raw ingredient and what was known about treatment in people.
Under US rules checked September 26, 2026, an ordinary pharmacy could not legally use raw MOTS-c to make a medicine. Compounding means preparing a medicine to meet a particular order.
- In the review checked September 30, 2026, FDA staff recommended keeping MOTS-c off the list of raw ingredients ordinary pharmacies may use.
- That recommendation was advice, rather than a final FDA decision about changing the list.
- A panel that advises FDA discussed MOTS-c on July 23, 2026. By September 30, 2026, no official record showing how the panel voted had been published by FDA.
- Under the rules checked September 26, 2026, even a vote in favour of MOTS-c would only be advice. FDA would need to change the rules before adding it to the list of ingredients pharmacies may use.
Questions that keep a result in context
Before relying on a headline, look for the answer to each of these.
- Was this MOTS-c itself or a different substance?
- Did people receive it, or were researchers measuring the body’s own levels?
- Were results made public, or was only a study plan posted?
- Does the result address the same concern I want help with?